


WE CLAIM:

1. A compound of formula I:



(I)

5 wherein:

Ar^1 is a cyclic group optionally substituted with one to five groups selected from $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_2\text{-C}_8$ alkenyl, $\text{C}_2\text{-C}_8$ alkynyl, hydroxy, $\text{C}_1\text{-C}_8$ alkoxy, $\text{C}_1\text{-C}_8$ alkylaryl, phenyl, aryl, $-\text{O-aryl}$, heteroaryl, cycloalkyl, $\text{C}_1\text{-C}_8$ alkylcycloalkyl, cyano, $-(\text{CH}_2)_n\text{NR}^6\text{R}^6$, $\text{C}_1\text{-C}_8$ haloalkyl, $\text{C}_1\text{-C}_8$ haloalkoxy, halo, $(\text{CH}_2)_n\text{COR}^6$, $(\text{CH}_2)_n\text{NR}^5\text{SO}_2\text{R}^6$, $-(\text{CH}_2)_n\text{C(O)NR}^6\text{R}^6$, 10 heterocyclic, and $\text{C}_1\text{-C}_8$ alkylheterocyclic; wherein the cycloalkyl, phenyl, aryl, and heterocyclic groups are each optionally substituted with one to three groups independently selected from hydroxy, $\text{C}_1\text{-C}_8$ alkoxyalkyl, $\text{C}_1\text{-C}_8$ haloalkoxy, $\text{C}_1\text{-C}_8$ alkyl, halo, $\text{C}_1\text{-C}_8$ haloalkyl, nitro, cyano, amino, carboxamido, phenyl, aryl, alkylheterocyclic, heterocyclic, and oxo;

15 L^1 is a bond or a divalent linker represented by the formula $\text{X}_2\text{-(CR}^3\text{R}^4\text{)}_m\text{-X}_3$ where X_2 is attached to Ar^1 and X_3 is attached to Ar^2 wherein R^3 and R^4 are independently selected from a bond, hydrogen, $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_2\text{-C}_8$ alkylene, $\text{C}_2\text{-C}_8$ alkynyl, phenyl, aryl, $\text{C}_1\text{-C}_8$ alkylaryl; wherein the alkyl, alkenyl, phenyl, and aryl groups are optionally substituted with one to five substituents independently selected from oxo, nitro, cyano, $\text{C}_1\text{-C}_8$ alkyl, 20 aryl, halo, hydroxy, $\text{C}_1\text{-C}_8$ alkoxy, $\text{C}_1\text{-C}_8$ haloalkyl, $(\text{CH}_2)_n\text{C(O)R}^6$, and $(\text{CH}_2)_n\text{CONR}^6\text{R}^6$;

X_2 is independently oxygen, $-\text{CH}$, $-\text{CONH}(\text{CR}^3\text{R}^4\text{)}_m$, $-\text{NHCO}(\text{CR}^3\text{R}^4\text{)}_m$, $-(\text{CR}^3\text{R}^4\text{)}_m$, $-\text{CHR}^6$, $-\text{NR}^5$, S , SO , SO_2 , $-\text{O}(\text{CR}^3\text{R}^4\text{)}_m$, or $-\text{S}(\text{CR}^3\text{R}^4\text{)}_m$;

X_3 is independently oxygen, $-\text{C}$, $-\text{CH}$, $-\text{CHR}^6$, $-(\text{CR}^3\text{R}^4\text{)}_m$, $-\text{NR}^5$, S , SO , or SO_2 ;

25 Ar^2 is a 5-member monocyclic heterocyclic aromatic group or positional isomer thereof, having 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen and sulfur; and wherein Ar^2 is optionally substituted with one to three substituents independently selected from $\text{C}_1\text{-C}_8$ alkyl, $\text{C}_2\text{-C}_8$ alkenyl, $\text{C}_2\text{-C}_8$ alkynyl, hydroxy, $\text{C}_1\text{-C}_8$ alkoxy, $\text{C}_1\text{-C}_8$ alkylaryl, phenyl, aryl, $\text{C}_3\text{-C}_8$ cycloalkyl, $\text{C}_1\text{-C}_8$ alkylcycloalkyl, cyano, $\text{C}_1\text{-C}_8$ haloalkyl,

halo, $(CH_2)_nC(O)R^6$, $(CH_2)_nC(O)OR^6$, $(CH_2)_nNR^5SO_2R^6$, $(CH_2)_nC(O)NR^6R^6$, and C_1-C_8 alkylheterocyclic;

Ar^3 is an optionally substituted bicyclic aromatic or non-aromatic group;

L^2 is a divalent linker represented by the formula $X_4-(CR^3R^4)_m-X_5$;

5 wherein X_4 is selected from the group consisting of C, -CH, CHR^6 , -CO, O, -NR⁵, -NC(O)-, -NC(S), -C(O)NR⁵, -NR⁶C(O)NR⁶, -NR⁶C(S)NR⁶, -SO₂NR⁷, -NRSO₂R⁷, and -NR⁶C(NR⁵)NR⁶;

10 X_5 is selected from the group consisting of O, -CH₂, -CH, -O(CR³R⁴)_m, NR³(CR³R⁴)_m, SO, SO₂, S, and SCH₂; wherein the group $X_4-(CR^3R^4)_m-X_5$ imparts stability to the compound of formula (1) and may be a saturated or unsaturated chain or divalent linker; R¹ and R² are independently hydrogen, C_1-C_8 alkyl, C_2-C_8 alkenyl, C_3-C_8 cycloalkyl, C_1-C_8 alkylaryl, -C(O)C₁-C₈ alkyl, -C(O)OC₁-C₈ alkyl, C₁-C₈ alkylcycloalkyl, (CH₂)_nC(O)OR⁵, (CH₂)_nC(O)R⁵, (CH₂)_nC(O)NR⁶R⁶, and (CH₂)_nNSO₂R⁵; wherein each of the alkyl, alkenyl, aryl are each optionally substituted with one to five groups

15 independently selected from C₁-C₈ alkyl, C₂-C₈ alkenyl, phenyl, and alkylaryl; and wherein R¹ and R² may combine together, and with the nitrogen atom to which they are attached or with 0, 1, 2 or 3 atoms adjacent to the nitrogen atom to form a nitrogen containing heterocycle which may have 1, or 2 substituents independently selected from C₁-C₈ alkyl, C₂-C₈ alkenyl, C₃-C₈ cycloalkyl, C₁-C₈ alkylaryl, -C(O)C₁-C₈ alkyl, -

20 C(O)OC₁-C₈ alkyl, C₁-C₈ alkylcycloalkyl, oxo, halo amino, and (CH₂)_nC(O)NR⁶R⁶; R⁵ is hydrogen, CN, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₅-C₈ alkylaryl, (CH₂)_nNSO₂C₁-C₈ alkyl, (CH₂)_nNSO₂phenyl, (CH₂)_nNSO₂aryl, -C(O)C₁-C₈ alkyl, or -C(O)OC₁-C₈ alkyl; and R⁶ and R⁶' are each independently hydrogen, C₁-C₈ alkyl, phenyl, aryl, C₁-C₈ alkylaryl, C₁-C₈ alkylcycloalkyl, or C₃-C₈ cycloalkyl;

25 R⁷ is hydrogen, C₁-C₈ alkyl, phenyl, aryl, C₁-C₈ alkylaryl, or C₃-C₈ cycloalkyl, and wherein m is an integer from 1 to 8; and n is an integer from 0 to 8; or a pharmaceutically acceptable salt, solvate, racemate, or enantiomer diastereomer or mixture of diastereomers thereof.

30 2. A compound according to Claim 1 wherein the group Ar¹ is selected from the group consisting of: phenyl, benzothiophene, benzofuran, or naphthyl.

3. A compound according to Claim 1 wherein the group L^1 is a linker selected from the group consisting of: $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{SCH}_2-$, $-\text{OCH}_2-$, $-\text{CH}_2\text{SCH}_2-$, $-\text{CH}_2\text{OCH}_2-$, or $-\text{OCH}_2\text{CH}_2\text{SCH}_2-$.

5 4. A compound according to Claim 1 wherein Ar^3 is an aromatic group selected from the group consisting of: indole, naphthyl, tetrahydronaphthyl, isoindolinone, isoquinolone, benzothiophene, or benzofuran.

10 5. A compound of Claim 1 wherein Ar^2 is a 4 or 5 member aromatic group selected from the group consisting of: oxazole, oxadiazole, or furan.

6. A compound according to Claim 1 wherein the linker (L^2) is: $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, or $-\text{CH}_2\text{CH}_2\text{CH}_2-$.

15 7. A compound according to Claim 1 wherein R^1 and R^2 combine with the nitrogen atom to form piperidinyl, pyrrolidinyl, azepine, or azetidinyl.

20 8. A compound according to Claim 1 wherein R^1 and R^2 are independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, methylcyclopentane, methylcyclohexane, phenyl, benzyl, cyclopentyl, cyclohexyl, methylcyclopropane and methylcyclobutane.

9. A compound according to Claim 1 wherein the group Ar^3 is naphthyl group.

25 10. A compound according to Claim 7 wherein the group Ar^2 is selected from oxazole or oxadiazole.

11. A compound according to Claim 8 wherein the group Ar^2 is selected from oxazole or oxadiazole.

30 12. A compound according to Claim 1 wherein at least one of L^1 and L^2 has a chain length of 3 to 5 atoms.

13. A compound selected from the group consisting of:

Dimethyl-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-benzofuran-2-ylmethyl}-amine oxalate,

5 Dimethyl-{5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-benzofuran-2-ylmethyl}-amine oxalate,

{1-Methanesulfonyl-5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-dimethyl-amine,

Dimethyl-{5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-amine oxalate,

10 {1-Methanesulfonyl-6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-dimethyl-amine,

Dimethyl-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-amine,

15 Dimethyl-{1-methyl-6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-2-ylmethyl}-amine oxalate,

Dimethyl-{5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-3-ylmethyl}-amine oxalate,

Dimethyl-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-3-ylmethyl}-amine maleate,

20 Dimethyl-{1-methyl-5-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-indol-3-ylmethyl}-amine oxalate,

Dimethyl-{4-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-naphthalen-1-yl}-amine,

25 Dimethyl-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-naphthalen-2-ylmethyl}-amine,

2-(2-Phenoxy-ethylsulfanylmethyl)-5-(6-pyrrolidin-1-ylmethyl-naphthalen-2-yl)-[1,3,4]oxadiazole maleate,

1-{6-[5-(2-phenoxy-ethylsulfanylmethyl)-[1,3,4]oxadiazol-2-yl]-naphthalen-2-ylmethyl}-


30 piperidine,

2-(2-piperidinoethyl)-5-{2-[(2-phenoxyethyl)thio)methyl]-1,3,4-oxadiazol-5-yl}isoindolin-1-one,



2-[(2-Phenoxyethyl)thio]methyl]-5-{3-hydroxymethyl-4-[(2-piperidinoethyl)amino]carbonyl]phenyl}-1,3,4-oxadiazolo,

5 2-(2-piperidinoethyl)-5-{2-[(2-phenoxyethyl)thio)methyl]-1,3,4-oxadiazol-5-yl}isoindolin-1-one, and pharmaceutically acceptable salt, solvate, enantiomer, prodrug, diastereomer or mixture thereof.


14. A compound selected from the group consisting of:



10



, and



or pharmaceutically acceptable salt, racemate, solvate, enantiomer or diastereomer or mixture of diastereomers thereof.

15

15. The compound of any one of Claims 1-14 which is the hydrochloride salt.

16. A method of treating Type II Diabetes comprising administering to a patient in need thereof a compound of any one of Claims 1-14.

20

17. A method of treating obesity and Related Diseases comprising administering to a patient in need thereof a compound of any one of Claims 1-14.

18. A method of inhibiting release of the melanin concentrating hormone comprising administering to a patient in need thereof a compound of any one of Claims 1-14.

5 19. A pharmaceutical formulation comprising a compound of any one of Claims 1-14 and a pharmaceutical carrier.

10 20. Use of a compound according to any one of Claims 1-14 for the manufacture of a medicament for treating and/or preventing Type II diabetes, obesity and/or Related Diseases.